Merck breaks below $139.50 after nemtabrutinib trial ends
Merck fell below $139.50 after ending its Phase 3 nemtabrutinib trial. FxPro sees $129.00 as the next support and says a daily close above $139.50 would cancel its bearish scenario.
Topic
Topic
Merck fell below $139.50 after ending its Phase 3 nemtabrutinib trial. FxPro sees $129.00 as the next support and says a daily close above $139.50 would cancel its bearish scenario.